The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.
The UK's Medicines and Healthcare products Regulatory Authority has approved the SARS-CoV-2 vaccine from Oxford University and AstraZeneca, the Guardian reports.
Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.
Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
